Date: 2011-05-05
Type of information:
phase: 2
Announcement: results
Company: Santhera Pharmaceutical (Switzerland)
Product: Catena® (idebenone)
Action mechanism:
Disease: Friedreich's ataxia
Therapeutic area: Neurodegenerative diseases
Country:
Trial
details: The 12-month IONIA-E study was an open-label extension study following the 6-month randomized controlled IONIA trial. The 68 participants enrolled into the IONIA-E study received high dose (1350/2250 mg/day for patients below/above 45 kg body weight) Catena®. Changes in the International Cooperative Ataxia Rating Scale (ICARS) and Friedreich's Ataxia Rating Scale (FARS) total scores and subscores were evaluated during the total of 18 months period for the combined IONIA and IONIA-E studies.
Latest
news: Santhera Pharmaceuticals has announced that it will present positive data from an open-label extension study (IONIA-E) evaluating Catena® for the treatment of Friedreich's Ataxia. The findings indicate that Catena® can offer therapeutic benefit to pediatric patients by improving overall neurological function, particularly fine motor skills, and speech. Data will be presented by the principal investigator of the study, Dr. David Lynch from Children's Hospital of Philadelphia (CHOP) on May 7 2011 in Strasbourg, France at the 4th International Friedreich's Ataxia Scientific Conference.
Throughout the combined treatment period, all ICARS subscores showed an improvement with the exception of posture and stance subscore. Patients improved with statistical significance for the eye (p<0.0001), speech (p<0.0001) and upper/lower limb ataxia (p<0.0001) ICARS subscores over the 18 months combined study period. The subgroup of patients who received high dose Catena® from the beginning of the IONIA study (N=22) significantly improved in neurological function over the 18 months of the combined study period (change in total ICARS -3.0 over baseline, p=0.014) suggesting a positive long-term benefit for patients suffering from this chronic disease. The ICARS total score for all patients combined (N=68) showed a mean change of -1.03 points (p=0.132) from baseline, indicating a trend for improvement in neurological function. Comparable data were obtained with the FARS.
